Business, energy, technology, markets and global industry news from Business News Today

Alkermes plc

PharmaDeviceNews Alkermes plc
Infographic highlighting Alkermes’ 180-patient Phase 2 ALKS 7290 depression trial, featuring a neural brain illustration and key details about orexin activation alongside antidepressants and safety evaluation.
Pharma & Biotech

Alkermes launches 180-patient Phase 2 ALKS 7290 trial testing orexin activation in major depression

Alkermes starts a 180-patient Phase 2 ALKS 7290 depression trial, testing orexin activation alongside antidepressants and assessing safety.

Read More
Lundbeck’s investigational orexin 2 receptor agonist Lu AH69593 has received FDA Fast Track designation as competition intensifies to develop new narcolepsy treatments targeting sleep-wake regulation. Representative image.
Pharma & Biotech

Lundbeck has FDA Fast Track status for Lu AH69593, but can it catch the narcolepsy orexin leaders?

Lundbeck’s Lu AH69593 gains FDA Fast Track status, but its Phase 1 narcolepsy programme enters an increasingly competitive orexin field.

Read More
Representative image: Alkermes’ alixorexton narcolepsy type 2 study highlights the potential of orexin receptor therapy to improve daytime wakefulness as Phase 3 testing examines dosing, safety and broader clinical benefit.
Pharma & Biotech

Alkermes’ alixorexton improves narcolepsy type 2 symptoms as Phase 3 risk comes into focus

Discover how Alkermes’ alixorexton could reshape narcolepsy type 2 treatment as Phase 3 tests its efficacy, dosing and long-term safety.

Read More